Jointly Provided by St. Joseph’s Hospital and Medical Center and MandatoryCE, LLC.


This activity is supported by an educational grant from Sanofi US.


This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit


This activity is supported by an educational grant from Novo Nordisk Inc.


This activity is supported by an educational grant from Merck Sharp & Dohme Corp.


Developed in collaboration with:

Pulaski County Medical Society

Arkansas Department of Health Chronic Disease Prevention and Control Branch

Arkansas Coalition for Obesity Prevention

Arkansas Academy of Physician Assistants

Arkansas Foundation for Medical Care













































































































































































































Looking for CDC Publications? Search the Stacks!



Links & Resources



























































































































































































































AR Diabetes



7:00am Registration, Breakfast in Exhibit Area
7:55am Welcome and Introduction
8:00am Update on T2DM and Obesity from the Arkansas Department of Health, including Epidemiology and Current Initiatives
8:30am Nutrition Therapy Recommendations
9:15am The Overlap of Metabolic Syndrome and Prediabetes: Pathophysiology, Early Identification and Intervention
9:45am Practical Tools and Guidelines for Managing Obesity in Patients with T2DM
10:30am Break, Refreshments in Exhibit Area
11:00am Overview of Current Treatment Options: Comparing Efficacy and Adverse Events
11:30am Update on Novel Antidiabetic Agents: Focus on SGLT2s, Incretins, Insulins, and Combination Therapies
12:30pm Q&A Panel Discussion
1:00pm Adjourn


Register today for this complimentary symposium by clicking the link below or calling 888-YourCE1 (888-968-7231).


Target Audience
This activity is designed for family practice and other primary care physicians, endocrinologists, nurse practitioners, physician assistants, registered nurses, pharmacists, diabetes educators, registered dietitians, and other healthcare professionals who care for patients with type 2 diabetes mellitus (T2DM).

Learning Objectives
At the conclusion of this activity, participants should be better able to:

  1. Recognize T2DM and obesity statistics in Arkansas and explain current initiatives/resources through the Department of Health.
  2. Review and apply concepts of nutrition therapy to improve diet and weight loss in patients with T2DM.
  3. Explain the pathophysiology, risk factors and diagnostic criteria of metabolic syndrome, as well as management strategies to reduce diabetes risk.
  4. Utilize current evidence-based guidelines as they relate to obesity screening, diagnosis, treatment, and individualization of care.
  5. Describe the mechanism of action, efficacy and safety of current drug classes as monotherapy and in combination.
  6. Review current evidence-based guidelines and apply individualized strategies for the use of novel antidiabetic agents including SGLT2s, incretins, insulins, and combination therapies.

Activity Goal/Desired Result
Improved clinical performance through increased knowledge and practice-based utilization of current evidence-based treatments and guidelines, and nutrition therapy recommendations; greater recognition and management of factors that have an impact on managing type 2 diabetes mellitus (T2DM), including lifestyle, metabolic syndrome, and obesity.

Summary of Identified Practice Gaps and Educational Needs
Statistics from the Centers for Disease Control and Prevention (CDC), report that over 29 million Americans are living with diabetes, and about 86 million are living with prediabetes. Obesity or being overweight remains the number one risk factor for T2DM. In 2015, Arkansas had the 6th highest obesity rates in the U.S. and was ranked 7th in having the highest type 2 diabetes rates.

The rise in obesity rates among adults corresponds to an increase in the incidence of metabolic syndrome, a proven, highly significant risk factor for type 2 diabetes mellitus (T2DM). An examination of current evidence and guidelines could assist healthcare providers in the assessment and management of obesity and metabolic syndrome, thereby reducing the risk for progression to T2DM, cardiovascular disease, and stroke.

Nutrition therapy continues to evolve and is a key component of diabetes management. Current recommendations are highly effective when individualized for each patient based on factors such as health goals, culture, access to healthful choices, and readiness to change.

There are more than 10 drug classes for the management of T2DM. These include newer agents with novel mechanisms of action to help in the individualization of care and optimization of treatment. Also, newly approved combination therapies can enhance treatment adherence, resulting in improved glycemic control and reduced costs.

The 2017 Arkansas Diabetes Symposium will present current information and evidence-based strategies on these topics. Clinicians will assess case studies using an interactive audience response system to increase knowledge, improve competence, and help facilitate change in performance and professional practice.

CME Accreditation and Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of St. Joseph’s Hospital and Medical Center, and MandatoryCE. St. Joseph’s Hospital and Medical Center is accredited by the ACCME to provide continuing medical education for physicians.

St. Joseph’s Hospital and Medical Center designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This Live activity, 2017 Arkansas Diabetes Symposium: Focus on Treatment Advances, Nutrition Therapy, Obesity and Metabolic Syndrome, with a beginning date of 10/28/2017, has been reviewed and is acceptable for up to  4.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit
This continuing nursing education activity was approved by the Western Multi-State Division, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. (4.5 contact hours) Arizona, California, Colorado, Idaho, and Utah Nurses Associations are members of the Western Multi-State Division.

CDR Credit
This activity has been approved by the Commission on Dietetic Registration for 4.5 CPEUs.

Note to Pharmacists:
The Arkansas State Board of Pharmacy accepts CME Credit designated as AMA PRA Category 1 toward continuing education requirements. Pharmacist who complete this activity will receive a CME participation certificate.


Registration for Little Rock, AR - Saturday, October 28, 2017


Faculty Bios and Disclosures

Philip Levy, MD, MACE
Dr. Levy is a clinical professor of medicine at the University of Arizona College of Medicine, and is chairman of the Section of Endocrinology and Metabolism at Banner Good Samaritan Regional Medical Center in Phoenix, Arizona, as well as past chief of staff and past chairman of medicine. He has practiced clinical endocrinology at Phoenix Endocrinology Clinic, LTD in Phoenix for more than 40 years. Dr. Levy graduated from the University of Pittsburgh School of Medicine in Pittsburgh, PA. He completed his internship, internal medicine residency, and fellowship in metabolism and endocrinology at Michael Reese Hospital and Medical Center in Chicago, Illinois. Dr. Levy was a research fellow in endocrinology at Guy’s Hospital Medical Center in London, England.

Dr. Levy served on the American Association of Clinical Endocrinologists (AACE) Board of Directors for six years, is past president of the American College of Endocrinology and currently serves as editor-in-chief of The First Messenger. He is past president and founding member of the board of directors of the Arizona Diabetes Association (ADA). Dr. Levy is an active member of AACE, American Medical Association and ADA in numerous capacities. He is a past member of The American Diabetes Association Board of Directors. He is also an Arizona Division of Motor Vehicles Medical Advisory Board Member, member of the Arizona Blue Shield, The Endocrine Society, American College of Physicians, Society of Nuclear Medicine, Arizona Medical Association, Clinical Endocrinology Editorial Board, and Endocrine Today Editorial Board. Dr. Levy is former Diabetes Forecast editor in chief and Clinical Diabetes editorial board member. He is a past editorial board member of Endocrine Practice. He is also a life member of the National Registry of Who’s Who.

Dr. Levy was presented the AACE Yank D. Coble, Jr., M.D., Distinguished Service Award in 2000 and the Master of the American College of Endocrinology Award in 2008.

Disclosure: Philip Levy, MD, MACE
Speakers Bureau: AstraZeneca, Janssen, Novo Nordisk


W. Timothy Garvey, MD, FACE
Dr. Garvey is Professor of Medicine, Chair of the Department of Nutrition Sciences, and Director of the UAB Diabetes Research Center at the University of Alabama at Birmingham. He obtained his MD degree, cum laude, from St. Louis University in 1978, and completed residency training in Internal Medicine at Barnes Hospital, Washington University, in 1981. He then was a clinical fellow in Endocrinology and Metabolism at the University of Colorado Health Sciences Center and University of California, San Diego School of Medicine. He subsequently held faculty posts at the University of California, School of Medicine (Assistant Professor), Indiana University School of Medicine (Associate and full Professor), and from 1994 to 2003 was the Director of the Division of Endocrinology, Diabetes, and Medical Genetics at the Medical University of South Carolina. Dr. Garvey moved to UAB on June 1, 2004.

Dr. Garvey has achieved international recognition for his research in the metabolic, molecular, and genetic pathogenesis of insulin resistance, Type 2 Diabetes, and obesity. His studies have involved the cellular and molecular biology of cell and animal models, metabolic investigations of human subjects on metabolic research wards, and the genetic basis of diseases in Gullah-speaking African Americans and other national cohorts of diabetes patients. He has brought basic technology directly to the study of human patients, and the combined approach of human physiology, genetics, and basic cell and molecular biology has provided the laboratory with a flexible capability for hypothesis testing relevant to human disease. By studying molecular parameters and differential gene expression in muscle and fat tissue from metabolically characterized individuals, the Garvey laboratory has made important observations regarding the pathogenesis of human insulin resistance. He has been a principle contributor to our understanding of the role of the glucose transport system and glucose transporter proteins in human insulin resistance, and the role of adiponectin in the metabolic syndrome. He has identified gene families that contribute to insulin resistance in human muscle insulin using cDNA microarray, e.g., NR4A orphan nuclear receptors and the tribbles gene family, and is using mitochondrial proteomics to better define mitochondrial defects that impair substrate oxidation.

Dr. Garvey has directed an independent laboratory since 1987 supported by the National Institutes of Health (NIDDK, NHLBI), the Department of Veterans Affairs, the AHA, JDFI, the ADA, and other agencies. He has served as the PI of the NIH-funded Diabetes Research Center since its initiation in 2008. Dr. Garvey currently serves on the editorial boards of the Diabetes Care, Metabolic Syndrome & Related Disorders, Cardiorenal Medicine, and Journal of Clinical Endocrinology and Metabolism. He is a member of the American Society for Clinical Investigation, the Association of American Physicians, the Endocrine Society, the American Diabetes Association, the Obesity Society, and the American Association of Clinical Endocrinologists.

Disclosure: W. Timothy Garvey, MD, FACE
Grant/Research Support: AstraZeneca, Eisai, Elcelyx, Lexicon, Merck, Novo Nordisk, Pfizer, Sanofi, Weight Watcher's
Honorarium/Expenses: Alexion, AstraZeneca, Eisai, Janssen, Merck, Novo Nordisk, Takeda
Major Stockholder: Bristol-Myers Squibb, ISIS, Lilly, Merck, Novartis, Pfizer


Appathurai Balamurugan, MD, DrPH, MPH
Dr. Balamurugan is a board-certified Family Physician and an epidemiologist. He obtained his medical degree from The Tamilnadu Dr. M.G.R Medical University, Chennai, India. He completed his family medicine residency from University of Arkansas for Medical Sciences College of Medicine, Department of Family and Preventive Medicine in Little Rock, Arkansas. He obtained his Master of Public Health with emphasis in Epidemiology from Tulane University School of Public Health and Tropical Medicine. He also recently earned his Doctorate in Public Health from UAMS College of Public Health.

Dr. Balamurugan has made significant contributions to both Medicine and Public Health over the past decade. His work has been published in national and internationally reputed journals several times. His work has been implemented at the State level, and has won national and international acclaim. Dr. Balamurugan’s multicenter cancer studies are the largest in the world of its kind, and the results from the study have been used to develop guidelines for clinical practice by the Centers for Disease Control and Prevention (CDC). His work on Diabetes was recognized as the, “Best Practice” in Diabetes Education by the Canadian Diabetes Association, and has won an international award at the 2007 International Annual meeting of American Telemedicine Association.

Dr. Balamurugan’s work on diabetes self-management education has been implemented across the State of Arkansas benefitting hundreds and thousands of people with diabetes in Arkansas. The work was also recognized by then Arkansas Governor Mike Huckabee, and also won, ‘Service in Science’ award by the Director of the Arkansas Department of Health Dr. Paul Halverson. He was honored as the “Chronic Disease Champion”, by the National Association of Chronic Disease Directors, in Washington, for his contribution in the field of chronic disease.

Disclosure: Appathurai Balamurugan, MD, DrPH, MPH
Nothing to disclose.


Debie Head, Ed.D, RD, LD, CDE
Dr. Head is an associate professor- nutrition specialist with the University of Arkansas, Division of Agriculture, Cooperative Extension Service. She has worked in the field of diabetes education for 20 years, as a clinical dietitian, diabetes educator, and instructor for graduate courses in diabetes education. In these various roles, she has counseled clients and their families, provided encouragement and education at diabetic support groups, established DSMT programs, worked with physicians to develop DM protocols, and trained dietetic interns in diabetes education. Debie completed her undergraduate and MSE at Harding University, her dietetic internship at UAMS, and her EdD at UALR. Currently Dr. Head is heavily involved in diabetes prevention and awareness promotion with the Cooperative Extension Service and is a NDPP lifestyle coach. She is a member of the Academy of Nutrition and Dietetics and the Diabetes Care and Education practice group.

Disclosure: Debie Head, Ed.D, RD, LD, CDE
Nothing to disclose.


Planning Committee

The following Planning Committee Members have stated they have nothing to disclose:
Richard Vanderpool, CHCP
Veronica Baez
Katherine Jorgensen, MSN/MBA, RN-BC, RNC-NIC, Hon.D
Robert T. Bailey, PharmD, MD, FAAFP


Special Needs and ADA Compliance 

Persons with special needs or a disability may request a reasonable accommodation, such as a dietary choices, sign language interpreter, etc., by contacting Richard Vanderpool at 888-YourCE1 (888-968-7231) or Requests should be made as early as possible to allow time to arrange the accommodation.


Registration for Little Rock, AR - Saturday, October 28, 2017